Influenza virus and Epstein-Barr virus peptides
| CEF product | Peptide sequence | Catalog no. | Quantity | GBP |
| CEF1, Influenza Matrix Protein M1 (58 – 66) | GILGFVFTL | AB-CEF001 | 1 mg | £105 |
| CEF2, Influenza Virus PA (46 – 54) | FMYSDFHFI | AB-CEF002 | 1 mg | £105 |
| CEF3, Influenza Virus M1 (13 – 21) | SIIPSGPLK | AB-CEF003 | 1 mg | £105 |
| CEF4, Influenza Virus NP (342 – 351) | RVLSFIKGTK | AB-CEF004 | 1 mg | £105 |
| CEF5, Influenza Virus NP (91 – 99) | KTGGPIYKR | AB-CEF005 | 1 mg | £105 |
| CEF6, Influenza Virus NP | LPFDKTTVM | AB-CEF006 | 1 mg | £105 |
| CEF7, Influenza Virus NP (380 – 388) | ELRSRYWAI | AB-CEF007 | 1 mg | £105 |
| CEF8, Influenza Virus NP (383 – 391) | SRYWAIRTR | AB-CEF008 | 1 mg | £105 |
| CEF9, Influenza Virus M1 128 – 135 | ASCMGLIY | AB-CEF009 | 1 mg | £105 |
| CEF10, Epstein – Barr Virus LMP2 (426 – 434) | CLGGLLTMV | AB-CEF010 | 1 mg | £105 |
| CEF11, Epstein – Barr Virus BMLF1 (280 – 288) | GLCTLVAML | AB-CEF011 | 1 mg | £105 |
| CEF12, Epstein – Barr Virus latent NA3B (399 – 408), AVF | AVFDRKSDAK | AB-CEF012 | 1 mg | £105 |
| CEF14, Epstein – Barr Virus RTA Protein (28 – 37) | DYCNVLNKEF | AB-CEF014 | 1 mg | £105 |
| CEF15, Epstein – Barr Virus Lytic Cycle Protein BZLF – 1(190 – 197) | RAKFKQLL | AB-CEF015 | 1 mg | £105 |
| CEF16, Epstein – Barr Virus latent NA – 3A (337 – 347) | FLRGRAYGL | AB-CEF016 | 1 mg | £105 |
| CEF17, Epstein – Barr Virus latent NA – 3A (158 – 166) | QAKWRLQTL | AB-CEF017 | 1 mg | £105 |
| CEF18, Epstein – Barr Virus latent NA – 3C (258 – 266) | RRIYDLIEL | AB-CEF018 | 1 mg | £105 |
| CEF19, Epstein – Barr Virus latent NA – 3A (458 – 466) | YPLHEQHGM | AB-CEF019 | 1 mg | £105 |
| CEF20, Cytomegalovirus, CMV pp65 (495 – 503) | NLVPMVATV | AB-CEF020 | 1 mg | £105 |
| CEF21, Cytomegalovirus, CMV pp65 (417 – 426) | TPRVTGGGAM | AB-CEF021 | 1 mg | £105 |
| CEF22, Cytomegalovirus, CMV pp65 (378 – 389) | SDEEEAIVAYTL | AB-CEF022 | 1 mg | £105 |
| CEF23, Cytomegalovirus, CMV pp65 (123 – 131) | IPSINVHHY | AB-CEF023 | 1 mg | £105 |
| CEF24, Influenza Virus PB1 Peptide (591 – 599) | VSDGGPNLY | AB-CEF024 | 1 mg | £105 |
| CEF25, Influenza Virus NP (44 – 52) | CTELKLSDY | AB-CEF025 | 1 mg | £105 |
| CEF26, Influenza Virus NP (265 – 274) | ILRGSVAHK | AB-CEF026 | 1 mg | £105 |
| CEF27, Epstein – Barr Virus BRLF – 1 lytic (148 – 156) | RVRAYTYSK | AB-CEF027 | 1 mg | £105 |
| CEF28, Epstein – Barr Virus latent NA – 3A (603 – 611) | RLRAEAQVK | AB-CEF028 | 1 mg | £105 |
| CEF29, Epstein – Barr Virus latent NA – 3B (416 – 424) | IVTDFSVIK | AB-CEF029 | 1 mg | £105 |
| CEF30, Epstein – Barr Virus BRLF1 (134 – 142) | ATIGTAMYK | AB-CEF030 | 1 mg | £105 |
| CEF31, Epstein – Barr Virus latent NA – 3A (379 – 387) | RPPIFIRRL | AB-CEF031 | 1 mg | £105 |
| CEF32, Epstein – Barr Virus latent NA – 3C (281 – 290) | EENLLDFVRF | AB-CEF032 | 1 mg | £105 |
| CEF33, Cytomegalovirus, HCMV pp65 | EFFWDANDIY | AB-CEF033 | 1 mg | £105 |
Related articles
Protein and peptide tags
Protein and peptide (epitope) tag sequences are attached to proteins to facilitate easy detection and purification of expressed proteins.
Custom Peptide Synthesis: Peptides for Raising Antibodies
In this article, we discuss methods for generating custom antibodies using peptide antigens including peptide antigen design considerations and options for generating antigenic peptides. In general, synthetic peptides are too small to elicit an immunogenic response.
Peptide synthesis: Storage and solubility
This article is the 3rd in a series on the synthesis of peptides. It looks at solubilising peptides and peptide storage. Peptides are supplied as lyophilised materials, which are regarded as stable compounds for shipping purposes.